Contribute Try STAT+ Today

The manufacturer of the Dsuvia painkiller, which was approved by the Food and Drug Administration amid substantial controversy, was taken to task by the agency for creating misleading ads that minimized the risks associated with the opioid medicine.

In a Feb. 11 warning letter, the FDA chastised AcelRx Pharmaceuticals (ACRX) of the “serious and potentially life-threatening risks” that may result from “accidental exposure to misplaced tablets” or overdoses involving the drug. The messages in question were used in a website banner ad and tabletop display that incorrectly suggested the extent to which Dsuvia is easy to administer as well as the proper daily dosage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.